Evidence map›Paper›PMID 34100981›Full record

ArticleCellular and molecular life sciences : CMLS2021

Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.

Thomas R Reich, Christian Schwarzenbach, Juliana Brandstetter Vilar, Sven Unger, Fabian Mühlhäusler, Teodora Nikolova, Alicia Poplawski, H Irem Baymaz, Petra Beli, Markus Christmann and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Chromenone Derivatives as CRM1 Inhibitors for Targeting Glioblastoma.Chembiochem : a European journal of chemical biology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Cellular senescence in glioma.Journal of neuro-oncology · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Thomas R Reich *Department of Toxicology, University Medical Center, Mainz, Germany.
Christian SchwarzenbachDepartment of Toxicology, University Medical Center, Mainz, Germany.
Juliana Brandstetter VilarDepartment of Toxicology, University Medical Center, Mainz, Germany.
Sven UngerDepartment of Toxicology, University Medical Center, Mainz, Germany.
Fabian MühlhäuslerDepartment of Toxicology, University Medical Center, Mainz, Germany.
Teodora NikolovaDepartment of Toxicology, University Medical Center, Mainz, Germany.
Alicia PoplawskiInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany.
H Irem BaymazInstitute of Molecular Biology (IMB), Johannes Gutenberg University, Mainz, Germany.
Petra BeliInstitute of Molecular Biology (IMB), Johannes Gutenberg University, Mainz, Germany.
Markus ChristmannDepartment of Toxicology, University Medical Center, Mainz, Germany.
Maja T Tomicic *Department of Toxicology, University Medical Center, Mainz, Germany. tomicic@uni-mainz.de.ORCID http://orcid.org/0000-0001-9289-4168
Johannes Gutenberg University Mainz · DE

Funding

Deutsche Forschungsgemeinschaft DFG-CH 665/6-1Deutsche Krebshilfe 70111404Wilhelm Sander-Stiftung 2019.154.1
6 · The paper itself

Abstract

To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization. Expression of nuclear export sequence (NES)-mutated Survivin (SurvNESmut-GFP) led to impaired colony formation upon TMZ. This was not due to enhanced cell death but rather due to increased senescence. Nuclear-trapped Survivin reduced homologous recombination (HR)-mediated double-strand break (DSB) repair, as evaluated by γH2AX foci formation and qPCR-based HR assay leading to pronounced induction of chromosome aberrations. Opposite, clones, expressing free-shuttling cytoplasmic but not nuclear-trapped Survivin, could repair TMZ-induced DSBs and evaded senescence. Mass spectrometry-based interactomics revealed, however, no direct interaction of Survivin with any of the repair factors. The improved TMZ-triggered HR activity in Surv-GFP was associated with enhanced mRNA and stabilized RAD51 protein expression, opposite to diminished RAD51 expression in SurvNESmut cells. Notably, cytoplasmic Survivin could significantly compensate for the viability under RAD51 knockdown. Differential Survivin localization also resulted in distinctive TMZ-triggered transcriptional pathways, associated with senescence and chromosome instability as shown by global transcriptome analysis. Orthotopic LN229 xenografts, expressing SurvNESmut exhibited diminished growth and increased DNA damage upon TMZ, as manifested by PCNA and γH2AX foci expression, respectively, in brain tissue sections. Consequently, those mice lived longer. Although tumors of high-grade glioma patients expressed majorly nuclear Survivin, they exhibited rarely NES mutations which did not correlate with survival. Based on our in vitro and xenograft data, Survivin nuclear trapping would facilitate glioma response to TMZ.

Indexed as

Cellular SenescenceDrug Resistance, NeoplasmHomologous RecombinationAnimalsAntineoplastic Agents, AlkylatingApoptosisBiomarkers, TumorBrain NeoplasmsCell NucleusCell ProliferationDNA DamageDNA RepairFemaleGene Expression Regulation, NeoplasticGlioblastomaHumansAntineoplastic Agents, AlkylatingBiomarkers, TumorBIRC5 protein, humanSurvivinTemozolomideAlkylation damageBIRC5Clastogenic effectsInhibitor of apoptosis (IAP)Nuclear export signal

Identifiers

PMID34100981
PMCPMC8257519
OpenAlexW3170963167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.